Cellular Biomedicine Group Stock Price, News & Analysis (NASDAQ:CBMG)

$19.20 -0.15 (-0.78 %)
(As of 01/17/2018 04:00 PM ET)
Previous Close$19.20
Today's Range$18.60 - $19.70
52-Week Range$5.05 - $22.40
Volume50,702 shs
Average Volume59,668 shs
Market Capitalization$269 million
P/E Ratio-11.10
Dividend YieldN/A
Beta2.82

About Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group logoCellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.

Receive CBMG News and Ratings via Email

Sign-up to receive the latest news and ratings for CBMG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CBMG
CUSIPN/A
Phone+1-408-9737884

Debt

Debt-to-Equity RatioN/A
Current Ratio4.94%
Quick Ratio4.94%

Price-To-Earnings

Trailing P/E Ratio-11.0982658959538
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$630,000.00
Price / Sales426.97
Cash FlowN/A
Price / CashN/A
Book Value$4.62 per share
Price / Book4.16

Profitability

Trailing EPS($1.73)
Net Income$-28,200,000.00
Net Margins-7,579.14%
Return on Equity-42.56%
Return on Assets-40.22%

Miscellaneous

Employees109
Outstanding Shares14,010,000

Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions

What is Cellular Biomedicine Group's stock symbol?

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

How will Cellular Biomedicine Group's stock buyback program work?

Cellular Biomedicine Group announced that its board has approved a share repurchase program on Sunday, June 4th 2017, which permits the company to repurchase $10,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's management believes its shares are undervalued.

How were Cellular Biomedicine Group's earnings last quarter?

Cellular Biomedicine Group Inc (NASDAQ:CBMG) issued its earnings results on Thursday, November, 9th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter. Cellular Biomedicine Group had a negative return on equity of 42.56% and a negative net margin of 7,579.14%. View Cellular Biomedicine Group's Earnings History.

When will Cellular Biomedicine Group make its next earnings announcement?

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Cellular Biomedicine Group.

Where is Cellular Biomedicine Group's stock going? Where will Cellular Biomedicine Group's stock price be in 2018?

1 analysts have issued 12 month price objectives for Cellular Biomedicine Group's shares. Their forecasts range from $18.00 to $18.00. On average, they expect Cellular Biomedicine Group's share price to reach $18.00 in the next twelve months. View Analyst Ratings for Cellular Biomedicine Group.

Who are some of Cellular Biomedicine Group's key competitors?

Who are Cellular Biomedicine Group's key executives?

Cellular Biomedicine Group's management team includes the folowing people:

  • Terry A. Belmont, Chairman of the Board (Age 69)
  • Bizuo Liu, Chief Executive Officer, Interim Chief Financial Officer, Secretary (Age 50)
  • Xia Meng, Chief Operating Officer
  • Yihong Yao Ph.D., Chief Scientific Officer
  • Richard L. Wang Ph.D., Chief Operation Officer
  • Zhou Hansheng, Director
  • Gerardus A. Hoogland, Director (Age 59)
  • Gang Jacky Ji, Director (Age 41)
  • Hansheng Zhou, Non-Executive Director
  • Chun Kwok Alan Au, Independent Director (Age 42)

How do I buy Cellular Biomedicine Group stock?

Shares of Cellular Biomedicine Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellular Biomedicine Group's stock price today?

One share of Cellular Biomedicine Group stock can currently be purchased for approximately $19.20.

How big of a company is Cellular Biomedicine Group?

Cellular Biomedicine Group has a market capitalization of $269 million and generates $630,000.00 in revenue each year. The biotechnology company earns $-28,200,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. Cellular Biomedicine Group employs 109 workers across the globe.

How can I contact Cellular Biomedicine Group?

Cellular Biomedicine Group's mailing address is 19925 Stevens Creek Blvd Ste 100, CUPERTINO, CA 95014-2384, United States. The biotechnology company can be reached via phone at +1-408-9737884 or via email at [email protected]


MarketBeat Community Rating for Cellular Biomedicine Group (CBMG)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  60 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  108
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cellular Biomedicine Group (NASDAQ:CBMG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.00$18.00$18.00$18.00
Price Target Upside: 100.00% upside100.00% upside100.00% upside239.62% upside

Cellular Biomedicine Group (NASDAQ:CBMG) Consensus Price Target History

Price Target History for Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group (NASDAQ:CBMG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/29/2017Maxim GroupSet Price TargetBuy$18.00HighView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Cellular Biomedicine Group (NASDAQ:CBMG) Earnings History and Estimates Chart

Earnings by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group (NASDAQ CBMG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018($0.40)N/AView Earnings Details
11/9/2017Q3 2017($0.43)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.43)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.43)ViewN/AView Earnings Details
3/14/2017Q4 2016($0.43)($0.43)$0.06 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.54)ViewN/AView Earnings Details
8/9/2016Q216($0.52)$0.07 millionViewN/AView Earnings Details
5/9/2016Q1 2016($0.35)ViewN/AView Earnings Details
3/14/2016Q415($0.42)($0.43)$1.50 million$0.62 millionViewN/AView Earnings Details
11/13/2015Q3($0.43)($0.44)$0.63 millionViewN/AView Earnings Details
8/14/2015Q215($0.37)($0.44)$0.66 millionViewN/AView Earnings Details
5/18/2015Q115($0.40)($0.39)$0.60 millionViewN/AView Earnings Details
3/31/2015($0.32)($0.57)ViewN/AView Earnings Details
11/19/2014Q3 2014($0.30)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.29)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cellular Biomedicine Group (NASDAQ:CBMG) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cellular Biomedicine Group (NASDAQ:CBMG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cellular Biomedicine Group (NASDAQ CBMG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 4.03%
Insider Trades by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)
Institutional Ownership by Quarter for Cellular Biomedicine Group (NASDAQ:CBMG)

Cellular Biomedicine Group (NASDAQ CBMG) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/22/2017Andrew K. ChanSVPBuy8,333$12.00$99,996.00View SEC Filing  
12/22/2017Tony LiuCEOBuy29,167$12.00$350,004.00View SEC Filing  
12/22/2017Yihong YaoInsiderBuy4,167$12.00$50,004.00View SEC Filing  
6/6/2017Tony LiuCEOBuy10,000$6.83$68,300.00119,825View SEC Filing  
2/22/2016Andrew K ChanSVPSell1,307$18.22$23,813.54147,054View SEC Filing  
2/17/2016Andrew K. ChanSVPSell1,516$17.76$26,924.16145,747View SEC Filing  
1/21/2016Andrew K. ChanSVPSell2,812$12.90$36,274.80145,747View SEC Filing  
12/21/2015Andrew K. ChanSVPSell12,812$21.94$281,095.28142,945View SEC Filing  
11/23/2015Andrew K. ChanSVPSell5,332$20.64$110,052.48155,757View SEC Filing  
10/21/2015Wei (William) CaoCEOSell20,000$19.59$391,800.00222,518View SEC Filing  
10/20/2015Andrew K. ChanSVPSell5,215$20.20$105,343.00159,793View SEC Filing  
9/21/2015Andrew K. ChanSVPSell27,927$20.80$580,881.60162,196View SEC Filing  
12/23/2014Pak To LeungMajor ShareholderSell142,857$14.00$1,999,998.00View SEC Filing  
6/26/2014David BolocanDirectorBuy10,000$5.00$50,000.00View SEC Filing  
5/22/2014Tony LiuCFOBuy100,000$5.00$500,000.00View SEC Filing  
7/23/2013Keith WongDirectorSell320,050$0.13$41,606.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cellular Biomedicine Group (NASDAQ CBMG) News Headlines

Source:
DateHeadline
Cellular Biomedicine Group Inc (CBMG) Insider Yihong Yao Acquires 4,167 SharesCellular Biomedicine Group Inc (CBMG) Insider Yihong Yao Acquires 4,167 Shares
www.americanbankingnews.com - December 28 at 5:16 PM
Cellular Biomedicine Group Inc (CBMG) SVP Andrew K. Chan Buys 8,333 SharesCellular Biomedicine Group Inc (CBMG) SVP Andrew K. Chan Buys 8,333 Shares
www.americanbankingnews.com - December 28 at 5:10 PM
Insider Buying: Cellular Biomedicine Group Inc (CBMG) CEO Acquires 29,167 Shares of StockInsider Buying: Cellular Biomedicine Group Inc (CBMG) CEO Acquires 29,167 Shares of Stock
www.americanbankingnews.com - December 28 at 3:42 PM
ETFs with exposure to Cellular Biomedicine Group, Inc. : December 28, 2017ETFs with exposure to Cellular Biomedicine Group, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 12:37 PM
Cellular Biomedicine Group Announces Closing of $14.5 Million Private Placement OfferingCellular Biomedicine Group Announces Closing of $14.5 Million Private Placement Offering
finance.yahoo.com - December 28 at 12:37 PM
Cellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Cellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 5:04 PM
BRIEF-Cellular Biomedicine Group reports qtrly ‍loss per share $0.43BRIEF-Cellular Biomedicine Group reports qtrly ‍loss per share $0.43
www.reuters.com - November 11 at 11:52 AM
Cellular Biomedicine Group Opens its New Shanghai GMP Facility and Joint LaboratoryCellular Biomedicine Group Opens its New Shanghai GMP Facility and Joint Laboratory
finance.yahoo.com - November 7 at 7:56 PM
BRIEF-Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processesBRIEF-Thermo Fisher Scientific and Cellular Biomedicine announce partnership to develop manufacturing processes
www.reuters.com - November 6 at 6:11 PM
Cellular Bio teams up with Fisher Scientific to build automated cell therapy manufacturing systemCellular Bio teams up with Fisher Scientific to build automated cell therapy manufacturing system
seekingalpha.com - November 6 at 6:11 PM
Thermo Fisher Scientific and Cellular Biomedicine Group Announce Strategic Partnership to Develop Manufacturing ProcessesThermo Fisher Scientific and Cellular Biomedicine Group Announce Strategic Partnership to Develop Manufacturing Processes
finance.yahoo.com - November 6 at 6:11 PM
Contrasting Cellular Biomedicine Group (CBMG) and Its PeersContrasting Cellular Biomedicine Group (CBMG) and Its Peers
www.americanbankingnews.com - November 6 at 3:15 PM
Cellular Biomedicine Group Executives to Present at Biotech and Money World HealthEx Forum in LondonCellular Biomedicine Group Executives to Present at Biotech and Money World HealthEx Forum in London
finance.yahoo.com - October 31 at 6:09 PM
Cellular Biomedicine Group, Inc. (CBMG) Scheduled to Post Earnings on MondayCellular Biomedicine Group, Inc. (CBMG) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
Relative Strength Alert For Cellular Biomedicine GroupRelative Strength Alert For Cellular Biomedicine Group
www.thestreet.com - October 24 at 7:14 PM
BioCryst Pharmaceuticals (BCRX) and Cellular Biomedicine Group (CBMG) Critical SurveyBioCryst Pharmaceuticals (BCRX) and Cellular Biomedicine Group (CBMG) Critical Survey
www.americanbankingnews.com - October 22 at 8:22 PM
Cellular Biomedicine Group (CBMG) & The Competition Head-To-Head AnalysisCellular Biomedicine Group (CBMG) & The Competition Head-To-Head Analysis
www.americanbankingnews.com - October 22 at 2:08 PM
Cerveau Technologies, Inc. Signs Research Agreement with Columbia University Medical CenterCerveau Technologies, Inc. Signs Research Agreement with Columbia University Medical Center
www.businesswire.com - October 19 at 10:31 PM
Cellular Biomedicine (CBMG) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowCellular Biomedicine (CBMG) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 30 at 1:05 PM
Cellular Biomedicine Group Plans Grand Opening of its New Shanghai FacilityCellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility
finance.yahoo.com - September 22 at 10:19 AM
One Thing To Consider Before Buying Cellular Biomedicine Group Inc (CBMG)One Thing To Consider Before Buying Cellular Biomedicine Group Inc (CBMG)
finance.yahoo.com - September 20 at 5:45 PM
Cellular Biomedicine Group to Present at the Cantor Fitzgerald Global Healthcare ConferenceCellular Biomedicine Group to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 14 at 5:43 PM
This Chinese CAR-T Play is Worth Checking OutThis Chinese CAR-T Play is Worth Checking Out
seekingalpha.com - September 7 at 10:05 PM
ETFs with exposure to Cellular Biomedicine Group, Inc. : September 6, 2017ETFs with exposure to Cellular Biomedicine Group, Inc. : September 6, 2017
finance.yahoo.com - September 5 at 11:35 PM
Maxim Group Reiterates "$18.00" Price Target for Cellular Biomedicine Group, Inc. (CBMG)Maxim Group Reiterates "$18.00" Price Target for Cellular Biomedicine Group, Inc. (CBMG)
www.americanbankingnews.com - August 29 at 1:04 PM
Cellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Cellular Biomedicine Group, Inc. :CBMG-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:03 PM
Streetwise Reports Examines One Regenerative Medicine Firm to Keep a Close Eye OnStreetwise Reports Examines One Regenerative Medicine Firm to 'Keep a Close Eye On'
finance.yahoo.com - August 18 at 5:06 PM
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Given a $18.00 Price Target at Maxim GroupCellular Biomedicine Group, Inc. (NASDAQ:CBMG) Given a $18.00 Price Target at Maxim Group
www.americanbankingnews.com - August 9 at 6:46 PM
Cellular Biomedicine Group Reports Second Quarter and First Half 2017 Financial Results and Business HighlightsCellular Biomedicine Group Reports Second Quarter and First Half 2017 Financial Results and Business Highlights
finance.yahoo.com - August 8 at 4:43 PM
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Scheduled to Post Earnings on MondayCellular Biomedicine Group, Inc. (NASDAQ:CBMG) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 31 at 8:15 AM
Cellular Biomedicine Group, Inc. (CBMG) Short Interest Down 60.4% in JuneCellular Biomedicine Group, Inc. (CBMG) Short Interest Down 60.4% in June
www.americanbankingnews.com - July 16 at 7:06 AM
ETFs with exposure to Cellular Biomedicine Group, Inc. : July 11, 2017ETFs with exposure to Cellular Biomedicine Group, Inc. : July 11, 2017
finance.yahoo.com - July 11 at 5:59 PM
Cellular Biomedicine Group (CBMG) Annoucnes Dr. Xia Meng as New COO to Lead Commercialization of the Company’s CAR-T and Stem Cell ProductsCellular Biomedicine Group (CBMG) Annoucnes Dr. Xia Meng as New COO to Lead Commercialization of the Company’s CAR-T and Stem Cell Products
www.streetinsider.com - June 26 at 9:53 PM
BRIEF-Cellular Biomedicine Group announces stock repurchase programBRIEF-Cellular Biomedicine Group announces stock repurchase program
www.reuters.com - June 1 at 9:43 PM
Cellular Biomedicine Group (CBMG) Announces $10M Buyback ProgramCellular Biomedicine Group (CBMG) Announces $10M Buyback Program
www.streetinsider.com - June 1 at 9:43 PM
Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20
www.nasdaq.com - May 19 at 8:52 AM
BRIEF-Cellular Biomedicine adds second clinical site in the expansion of CAR-T Phase I clinical trialBRIEF-Cellular Biomedicine adds second clinical site in the expansion of CAR-T Phase I clinical trial
www.reuters.com - May 15 at 3:53 PM
BRIEF-Cellular Biomedicine Q1 net loss per share $0.43BRIEF-Cellular Biomedicine Q1 net loss per share $0.43
www.reuters.com - May 8 at 9:06 PM
Cellular Biomedicine reports 1Q lossCellular Biomedicine reports 1Q loss
marketbeat.com - May 8 at 5:36 PM
Is Cellular Biomedicine Group A Buy?Is Cellular Biomedicine Group A Buy?
seekingalpha.com - March 26 at 10:49 AM
BRIEF-Cellular Biomedicine had working capital of $38.3 mln as of Dec. 31BRIEF-Cellular Biomedicine had working capital of $38.3 mln as of Dec. 31
www.reuters.com - March 15 at 2:06 AM
CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K/A, Annual ReportCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K/A, Annual Report
biz.yahoo.com - March 14 at 9:04 PM
CELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K, Annual ReportCELLULAR BIOMEDICINE GROUP, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 14 at 11:12 AM
Cellular Biomedicine Group Reports Full-Year 2016 Financial Results and Recent Operational ProgressCellular Biomedicine Group Reports Full-Year 2016 Financial Results and Recent Operational Progress
us.rd.yahoo.com - March 14 at 11:12 AM
Exclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese MarketExclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese Market
www.benzinga.com - March 4 at 1:35 AM
Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) to Fund AlloJoin™ Allogeneic Stem Cell Therapy for Knee Osteoarthritis (KOA) in the U.S.Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) to Fund AlloJoin™ Allogeneic Stem Cell Therapy for Knee Osteoarthritis (KOA) in the U.S.
us.rd.yahoo.com - March 1 at 10:29 AM
Cellular Biomedicine Group (CBMG) Presents at 19th Annual BIO CEO & Investor ConferenceCellular Biomedicine Group (CBMG) Presents at 19th Annual BIO CEO & Investor Conference
seekingalpha.com - February 15 at 2:52 AM
Cellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on FebruaryCellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February
www.nasdaq.com - February 8 at 3:18 AM
Cellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February 13, 2017Cellular Biomedicine Group (CBMG) to Present at the 19th BIO CEO & Investor Conference on February 13, 2017
feeds.benzinga.com - February 7 at 9:19 AM
Cellular Biomedicine Group (CBMG) Gains Approval to Commence Phase I Trial for C-CAR011 in ChinaCellular Biomedicine Group (CBMG) Gains Approval to Commence Phase I Trial for C-CAR011 in China
www.streetinsider.com - January 9 at 10:21 PM

SEC Filings

Cellular Biomedicine Group (NASDAQ:CBMG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cellular Biomedicine Group (NASDAQ:CBMG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cellular Biomedicine Group (NASDAQ CBMG) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.